Target Price | $14.67 |
Price | $0.87 |
Potential |
1,582.92%
register free of charge
|
Number of Estimates | 3 |
3 Analysts have issued a price target Sonnet BioTherapeutics Holdings Inc 2025 .
The average Sonnet BioTherapeutics Holdings Inc target price is $14.67.
This is
1,582.92%
register free of charge
$30.00
3,342.34%
register free of charge
$7.00
703.21%
register free of charge
|
|
A rating was issued by 3 analysts: 3 Analysts recommend Sonnet BioTherapeutics Holdings Inc to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sonnet BioTherapeutics Holdings Inc stock has an average upside potential 2025 of
1,582.92%
register free of charge
|
Sep '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 0.15 | 0.10 |
57.14% | 33.33% | |
EBITDA Margin | -12,286.67% | -15,000.00% |
50.36% | 22.08% | |
Net Margin | -63,127.20% | -17,539.20% |
71.85% | 72.22% |
3 Analysts have issued a sales forecast Sonnet BioTherapeutics Holdings Inc 2024 . The average Sonnet BioTherapeutics Holdings Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Sonnet BioTherapeutics Holdings Inc 2024 . The average Sonnet BioTherapeutics Holdings Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $-18.4m | 35.56% |
---|---|---|
2024 |
$-15.0m
18.61%
Unlock
|
2023 | -12,286.67% | 50.36% |
---|---|---|
2024 |
-15,000.00%
22.08%
Unlock
|
The average Sonnet BioTherapeutics Holdings Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
2023 | -63,127.20% | 71.85% |
---|---|---|
2024 |
-17,539.20%
72.22%
Unlock
|
Sep '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -18.14 | -3.36 |
87.94% | 81.48% | |
P/E | negative | |
EV/Sales | 11.30 |
Based on analysts' sales estimates for 2024, the Sonnet BioTherapeutics Holdings Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Current | 18.83 | 137.15% |
---|---|---|
2024 |
11.30
39.99%
Unlock
|
Current | 75.50 | 57.48% |
---|---|---|
2024 |
45.30
40.00%
Unlock
|
Sonnet BioTherapeutics Holdings Inc...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.